Alnylam Pharmaceuticals Total Current Assets increased by 4.2% to $4.22B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.1%, from $3.27B to $4.22B. Over 5 years (FY 2020 to FY 2025), Total Current Assets shows an upward trend with a 9.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
A higher value relative to current liabilities indicates a strong safety margin for meeting short-term obligations.
The sum of all assets that are reasonably expected to be converted into cash or consumed within one year. This aggregate...
High-growth tech companies often maintain high current asset levels to support rapid scaling and R&D needs.
total_current_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.73B | $2.68B | $2.81B | $2.59B | $2.47B | $2.69B | $2.69B | $2.54B | $2.52B | $2.99B | $2.98B | $2.99B | $3.17B | $3.36B | $3.30B | $3.27B | $3.64B | $3.95B | $4.05B | $4.22B |
| QoQ Change | — | -1.8% | +5.0% | -7.8% | -4.6% | +8.9% | +0.1% | -5.6% | -0.7% | +18.3% | -0.1% | +0.2% | +6.2% | +5.8% | -1.8% | -0.8% | +11.5% | +8.5% | +2.5% | +4.2% |
| YoY Change | — | — | — | — | -9.3% | +0.6% | -4.1% | -1.9% | +2.1% | +10.9% | +10.8% | +17.6% | +25.7% | +12.4% | +10.5% | +9.4% | +14.8% | +17.8% | +22.9% | +29.1% |